As of July 2, 2025, Sensyne Health PLC has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.35, this represents a potential upside of -7674502.9%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -1950172.9% |
| Potential Upside (10-year) | -7674502.9% |
| Discount Rate (WACC) | 7.5% - 9.1% |
Revenue is projected to grow from $9 million in 04-2021 to $1611 million by 04-2031, representing a compound annual growth rate of approximately 68.0%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 04-2021 | 9 | 344% |
| 04-2022 | 30 | 228% |
| 04-2023 | 63 | 110% |
| 04-2024 | 112 | 79% |
| 04-2025 | 182 | 63% |
| 04-2026 | 285 | 57% |
| 04-2027 | 434 | 52% |
| 04-2028 | 629 | 45% |
| 04-2029 | 877 | 39% |
| 04-2030 | 1204 | 37% |
| 04-2031 | 1611 | 34% |
Net profit margin is expected to improve from -302% in 04-2021 to -298% by 04-2031, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 04-2021 | (28) | -302% |
| 04-2022 | (91) | -306% |
| 04-2023 | (190) | -304% |
| 04-2024 | (338) | -302% |
| 04-2025 | (547) | -301% |
| 04-2026 | (853) | -299% |
| 04-2027 | (1,300) | -299% |
| 04-2028 | (1,879) | -299% |
| 04-2029 | (2,618) | -299% |
| 04-2030 | (3,593) | -298% |
| 04-2031 | (4,802) | -298% |
. Projected CapEx is expected to maintain at approximately 639% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 04-2022 | 40 |
| 04-2023 | 120 |
| 04-2024 | 263 |
| 04-2025 | 495 |
| 04-2026 | 858 |
| 04-2027 | 1375 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 195 |
| Days Inventory | 0 |
| Days Payables | 1,535 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 6M/2022 | (25) | (1) | 95 | (14) | (106) |
| 2023 | (69) | (3) | 400 | (4) | (461) |
| 2024 | (74) | (6) | 714 | (2) | (780) |
| 2025 | (51) | (9) | 1163 | (46) | (1,157) |
| 2026 | 8 | (15) | 1822 | (9) | (1,790) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -1950172.9% |
| 10-Year DCF (Growth) | 0.00 | -7674502.9% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Sensyne Health PLC (SENS.L) a buy or a sell? Sensyne Health PLC is definitely a sell. Based on our DCF analysis, Sensyne Health PLC (SENS.L) appears to be overvalued with upside potential of -7674502.9%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.35.